Skip to contentP
Phathom Pharmaceuticals, Inc.
P
PHATPhathom Pharmaceuticals, Inc. Q2 2026 · 10-Q
Revenue$74.27M$74.27M+88.0% vs Q2 2025 Net Income-$17.58M-$17.58MN/M vs Q2 2025 EPS Diluted-$0.21-$0.21N/M vs Q2 2025 Gross Profit$59,178,000+71.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Phathom Pharmaceuticals, Inc. · CIK 1783183 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,930,000N/M Free Cash Flowderived-$1,974,000N/M Margins · derivedGross margin79.7%−7.6 pt vs Q2 2025
Operating margin-5.3%+146.4 pt vs Q2 2025
Net margin-23.7%+168.2 pt vs Q2 2025
ended Jun 30, 2026 · filed Jul 30, 2026 · 30 d after period end